Manages pain severe enough to require an opioid analgesic. ANDA 216049, held by Somerset Therapeutics. Nalbuphine Hydrochloride.
As of Nov 22, 2026, ANDA 216049 (Nalbuphine Hydrochloride), held by Somerset Therapeutics, was first approved by FDA on Sep 19, 2024, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Nalbuphine hydrochloride injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine hydrochloride injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. Limitations of Use: Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration, reserve nalbuphine hydrochloride injection for use in patients for whom alternative treatment options [e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2024 | Original application | Approved | None posted |
| Nalbuphine Hydrochloride100MG/10ML (10MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Rx |
| Nalbuphine Hydrochloride200MG/10ML (20MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Rx |
| Dec 22, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 19, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters